Written by the Nuvirox Research Team
Key Points
- ARTHROL (2024), a 142-person, 6-month RCT, found no significant difference between resveratrol and placebo for knee osteoarthritis pain (p=0.88).
- Earlier, smaller studies had hinted at benefit only when resveratrol was combined with an NSAID, not used alone.
- This is a rare case where a well-powered trial delivers a clean, useful negative result.
Short answer: no, according to the best trial we have. ARTHROL, a well-designed, 142-person, 6-month randomized controlled trial published in 2024, found that oral resveratrol performed no better than placebo for knee osteoarthritis pain. This is one of the more useful null results in the joint supplement space, precisely because the trial was rigorous.
Why Did Resveratrol Seem Promising in the First Place?
Resveratrol, the polyphenol found in red wine and grape skins, showed anti-inflammatory and chondroprotective (cartilage-protective) effects in lab and animal models of osteoarthritis, and earlier small studies had hinted at benefit when it was combined with an anti-inflammatory drug rather than used alone. That earlier signal is part of what motivated a larger, more rigorous trial.
Why Did a 6-Month Trial Only Report Results at 3 Months?
ARTHROL's primary outcome was defined at 3 months specifically, with 6-month follow-up used to check whether any effect held up over a longer window. This is a common and methodologically sound trial design choice, not a sign the researchers were fishing for a result — predefining the primary timepoint before the trial starts is exactly what prevents researchers from cherry-picking whichever timepoint happens to look best after the fact. The trial's null result held at both timepoints.
What Does This Null Result Mean for Antioxidant-Style Joint Supplements Generally?
It's a useful reminder not to treat "antioxidant" or "anti-inflammatory in lab studies" as a stand-in for "proven to reduce joint pain in people." Resveratrol looked just as promising in preclinical models as several other polyphenols still being studied, and it still failed a well-designed human trial. That track record argues for treating early, mechanism-only evidence for any joint ingredient with real caution until human trial data confirms or denies it, rather than assuming a plausible biological story will pan out.
How Does Resveratrol Compare to Grape Seed Extract, Another Grape-Derived Polyphenol?
Both come from grapes and both are antioxidant polyphenols, but they're chemically distinct compounds with different research trajectories. Grape seed extract hasn't yet been tested in a human joint pain RCT at all, while resveratrol has now been tested rigorously and shown not to work as a standalone treatment. That's an important distinction: an ingredient with no human data isn't the same as one with a clear negative human trial result, even though both currently lack positive human evidence for joint pain.
What Human Studies Actually Show
Unlike many joint supplement ingredients where the evidence is a patchwork of small, inconsistent trials, resveratrol now has one large, well-designed study with a clear answer.
ARTHROL was a double-blind, randomized, placebo-controlled Phase 3 trial across 3 French tertiary centers in adults with painful knee osteoarthritis (baseline pain score 56/100). Participants took oral resveratrol (tapering from 80mg/day to 40mg/day) or matched placebo for 6 months. At 3 months, knee pain dropped by a similar amount in both groups — a mean reduction of −15.7 points with resveratrol versus −15.2 with placebo, a difference that was not statistically significant (p = 0.88).
This is the headline finding, not a footnote: a p-value of 0.88 on the primary outcome, in a purpose-built, adequately sized trial, is about as clean a null result as this literature produces. It doesn't rule out that resveratrol could help as an add-on to other therapies (the earlier, smaller trials that inspired ARTHROL combined it with an NSAID), but as a standalone strategy for knee pain, the current best evidence doesn't support it.
What It Won't Do
Based on current evidence, resveratrol as a standalone joint pain strategy is not supported. If knee pain is significant or worsening, options with stronger direct evidence — or a clinical evaluation — are a better use of time and money than a supplement the best trial found ineffective for this specific purpose. This finding is specific to knee osteoarthritis pain; it doesn't speak to resveratrol's effects, if any, on unrelated health markers studied elsewhere.
Dosing and Timeline
Because the best-quality trial found no effect, we're not providing a dosing recommendation for joint pain here — that would imply an efficacy this evidence doesn't support. For reference, the ARTHROL trial used a tapering schedule from 80mg/day down to 40mg/day, adjusted specifically to manage known gastrointestinal tolerability issues with resveratrol at higher doses, not because that particular schedule was expected to outperform a flat dose.
Frequently Asked Questions
If resveratrol didn't work in the trial, why do some people say it helps them?
Individual reports can reflect natural fluctuation in osteoarthritis symptoms, the placebo effect, or other lifestyle changes made at the same time. That's exactly why placebo-controlled trials exist — to separate a real drug effect from those other factors.
Does this mean resveratrol has no health benefits at all?
No — this article is specifically about joint pain. Resveratrol has been studied for other purposes in other contexts, which is outside the scope of what ARTHROL tested.
Could a higher dose have worked better?
ARTHROL used a clinically reasonable, previously studied dose. There's no strong evidence that a different dose would flip a p=0.88 result into a meaningful effect.
Is resveratrol at least safe to take alongside a joint supplement?
The trial didn't report significant safety concerns at the doses used, but taking it purely for joint pain relief isn't well supported by this evidence.
Did the trial only enroll people with mild osteoarthritis, which might explain the null result?
No — participants were required to have a baseline pain intensity of at least 40 out of 100, meaning meaningful, active symptoms, not a mild or borderline population where a small effect might be harder to detect.
Could resveratrol still help when combined with a prescription anti-inflammatory, even though it doesn't work alone?
That possibility is exactly what motivated ARTHROL in the first place, based on earlier smaller add-on studies. ARTHROL itself tested resveratrol alone, so the combination question technically remains less settled than the standalone question ARTHROL answered.
How was the trial's dropout rate, and could that have skewed the result?
The trial reported a substantial screening-to-enrollment funnel (649 assessed, 142 enrolled) typical of rigorous randomized trials, and researchers use intention-to-treat analysis specifically to guard against dropout bias skewing results.
From Nuvirox
Why we formulated Joint+ Restore
Joint+ Restore is formulated to support everyday joint comfort, mobility, and long-term joint health as part of a broader routine that includes movement, a balanced diet, and healthy body weight. Joint+ Restore is currently being reformulated, so we're intentionally not listing specific ingredients or doses here — check the product page for the current label.
Backed by a 60-day money-back guarantee — long enough to actually evaluate whether it's making a difference for you.
Learn more about Joint+ Restore →The Bottom Line
This is one of the more clear-cut "no" answers in the joint supplement literature. If you're looking for a polyphenol-family option with more supportive human evidence for joint pain, quercetin has more consistent trial support. For the wider evidence landscape, see our ranking of joint supplement ingredients by evidence quality.
References
- Nguyen C, Coudeyre E, Boutron I, et al. Oral resveratrol in adults with knee osteoarthritis: A randomized placebo-controlled trial (ARTHROL). PLoS Med. 2024;21(8):e1004440. PMID: 39137167. doi:10.1371/journal.pmed.1004440
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.